One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Cronos Group  logo
Cronos Group CRON
$ 3.62 -2.43%
report update icon

Quarterly report 2026-Q3
added 11-05-2026

Cronos Group Income Statement 2025-2011 | CRON

Brief overview of financial results at Cronos Group

The comparison covers a five-year financial horizon. Cronos Group reported revenue of $46.7 million in 2020 and $147 million by 2025. The five-year change reached +213.8%, while CAGR stood at 25.7%. Revenue growth reflects a pronounced phase of business expansion.

The gross result shifted from −$25.8 million to $62.8 million, or +342.9%. At the margin level, the figure shifted from −55.3% to 42.8%. The margin shift points to a more favorable sales-and-cost structure.

EBITDA changed from −$176 million to −$3.2 million (+98.2%). Operating performance weakened relative to revenue. Comparing the endpoints gives EBITDA margins of −377.7% and −2.2%. The increased EBITDA share is a positive sign.

The final result was −73.1 million dollars initially and −2.9 million dollars in the final year. The loss reduction is constructive, but the recovery is incomplete.

Market capitalization changed from 3.6 billion dollars to 736 million dollars (−79.7%). The market is not yet fully reflecting the fundamental progress.

What the figures show

The results present an uneven picture without one dominant signal. The strongest signals are revenue expansion, positive operating leverage and better sales economics. The most visible risks are lower investor confidence and a low EBITDA margin. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement Cronos Group

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

736 M 963 M 663 M 1.08 B 1.37 B 3.63 B 2.31 B 3.17 B 1.21 B 108 M - - - - -

Shares

383 M 382 M 381 M 377 M 370 M 350 M 310 M 172 M 177 M 78.2 M - - - - -

Historical Prices

1.92 2.52 1.74 2.86 3.69 10.3 7.18 19.7 - - - - - - -

Net Income

-2.9 M 40 M -73.9 M -169 M -396 M -73.1 M 1.17 B -13.9 M 1.98 M -885 K 278 K -4.15 M -619 K - -

Revenue

147 M 118 M 87.2 M 86.7 M 64.6 M 46.7 M 23.8 M 11.5 M 3.25 M 412 K - - -196 K - -

Gross Profit

62.8 M 25.2 M 11.9 M 15.4 M -17.6 M -25.8 M -17.6 M 8.27 M 5.75 M 1.48 M -145 K -32.2 K -196 K - -

Operating Income

-17.4 M -76.5 M -84.8 M -111 M -292 M - - - - - - - - - -

Interest Expense

-241 K -301 K 1.03 M 13 K 27 K - - - - - - - - - -

EBITDA

-3.16 M -67.2 M -76.7 M -98.3 M -277 M -176 M -114 M -12.4 M -1.25 M -1.3 M -4.01 M -2.23 M -619 K - -

Operating Expenses

80.2 M 102 M 96.7 M 127 M 274 M 154 M 98.2 M 21.6 M 7.43 M 3.07 M 1.55 M 2.22 M 424 K - -

General and Administrative Expenses

42 M 46.5 M 49.5 M 67.7 M 90.9 M 95.9 M 60.9 M 15.9 M 7 M 2.78 M 1.47 M 2.02 M - - -

All numbers in USD currency

Quarterly Income Statement Cronos Group

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

369 M 374 M 379 M -316 K 383 M 385 M 383 M 95 K 382 M 382 M 381 M 64.4 K 381 M 381 M 381 M 561 M 378 M 376 M 375 M 1.29 M 372 M 372 M 363 M 2.18 M 350 M 349 M 349 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

17.8 M 35.7 M 15.7 M -491 K 28.3 M -38.5 M 7.72 M 43.9 M 7.32 M -8.76 M -2.48 M -45 M -1.77 M -8.5 M -19.3 M -78.9 M -36.9 M -20.3 M -32.7 M -134 M 77.7 M -179 M -161 M -111 M 69.5 M -107 M 76 M 61.6 M - - - -9.69 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

83.9 M 70.6 M 59 M 58.4 M 48.8 M 44.3 M 41.9 M 41.2 M 46.6 M 38.7 M 35.4 M 34 M 33.9 M 25.8 M 26.6 M 29.1 M 26.1 M 27.1 M 29.4 M 21.5 M 24.6 M 18.8 M 14.7 M 20 M 13.6 M 11.4 M 9.34 M 7.31 M - - - 4.28 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - - - - - - - - - - - - - - - - - - 8.33 M 4.61 M 6.34 M 7.47 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

32.3 M 28.5 M 19.2 M 16.2 M 18.3 M 14.5 M 13.7 M 10.8 M 3.61 M 6.3 M 4.48 M 1.91 M 3.97 M 3.1 M 2.93 M 1.26 M 3.14 M 4.32 M 6.93 M 1.88 M -730 K -15.8 M -2.96 M -14.9 M -1.54 M -2.92 M -6.48 M -20.4 M - - - 1.88 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

9.03 M 7.4 M -1.83 M -7.5 M -503 K -5.32 M -4.07 M -11.4 M -33.7 M -15.6 M -15.9 M -21.6 M -21.8 M -20.6 M -20.8 M -27 M -27.3 M -25.3 M -36 M 106 M -56.4 M -296 M -45.2 M -58.4 M -41.2 M -74.7 M -45.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- -2 K 10 K - -283 K -1 K 43 K 436 K -315 K 248 K -670 K 18 K 974 K 17 K 85 K 73 K -581 K 49 K 135 K -308 K 7 K 1.05 M -16 K -1.2 M -641 K -9 K -378 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

9.38 M 7.78 M -1.41 M -7.09 M -149 K -4.46 M -3.58 M -10.9 M -32.6 M -14.5 M -14.8 M -22.6 M -20.3 M -19.1 M -19.2 M -26.3 M -26.4 M -24.7 M -34.8 M 107 M -55.8 M -296 M -44.5 M -58.2 M -40.9 M -74.5 M -44.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

23.3 M 21 M 21 M 23.7 M 18.8 M 19.8 M 17.8 M 22.2 M 37.3 M 21.9 M 20.4 M 23.5 M 25.7 M 23.7 M 23.7 M 28.3 M 30.5 M 29.6 M 43 M -104 M 55.7 M 281 M 42.2 M 43.6 M 39.6 M 71.8 M 38.6 M -20.4 M - - - 1.88 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

12 M 10.8 M 11.7 M 12.9 M 9.25 M 10.5 M 9.31 M 12.1 M 12.8 M 12.8 M 8.91 M 9.8 M 14.4 M 13.5 M 11.9 M 13.9 M 16.4 M 16.3 M 22.4 M 14 M 32.5 M 22.4 M 21.9 M 19.5 M 18.9 M 18.4 M 23.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Cronos Group (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Drug manufacturers industry

Issuer Price % 24h Market Cap Country
Jupiter Wellness Jupiter Wellness
JUPW
- - $ 33.6 M usaUSA
Neoleukin Therapeutics Neoleukin Therapeutics
NLTX
- - $ 193 M canadaCanada
ProPhase Labs ProPhase Labs
PRPH
- - $ 5.07 M usaUSA
Zomedica Corp. Zomedica Corp.
ZOM
- -0.21 % $ 98 M usaUSA
Agile Therapeutics Agile Therapeutics
AGRX
- 10.11 % $ 58.2 M usaUSA
Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc
AVDL
- - $ 2.06 B franceFrance
Organogenesis Holdings Organogenesis Holdings
ORGO
$ 0.84 0.19 % $ 106 M usaUSA
Evoke Pharma Evoke Pharma
EVOK
- - $ 36.6 M usaUSA
Pacira BioSciences Pacira BioSciences
PCRX
$ 36.43 0.03 % $ 1.62 B usaUSA
Perrigo Company plc Perrigo Company plc
PRGO
$ 15.83 0.83 % $ 2.19 B usaUSA
Rockwell Medical Rockwell Medical
RMTI
$ 7.76 2.04 % $ 279 M usaUSA
Solid Biosciences Solid Biosciences
SLDB
$ 6.65 7.52 % $ 582 M usaUSA
Sundial Growers Sundial Growers
SNDL
$ 1.42 2.54 % $ 366 M canadaCanada
Tilray Tilray
TLRY
$ 2.91 3.56 % $ 325 M canadaCanada
Aerie Pharmaceuticals Aerie Pharmaceuticals
AERI
- - $ 754 M usaUSA
Alimera Sciences Alimera Sciences
ALIM
- - $ 142 M usaUSA
Veru Veru
VERU
$ 2.14 3.88 % $ 31.3 M usaUSA
Viatris Viatris
VTRS
$ 19.72 5.03 % $ 22.9 B usaUSA
Adamis Pharmaceuticals Corporation Adamis Pharmaceuticals Corporation
ADMP
- 0.86 % $ 117 M usaUSA
cbdMD cbdMD
YCBD
$ 0.42 6.96 % $ 1.69 M usaUSA
China Pharma Holdings China Pharma Holdings
CPHI
$ 0.57 8.66 % $ 2.45 M chinaChina
Lannett Company Lannett Company
LCI
- 1.15 % $ 7.11 M usaUSA
Zynerba Pharmaceuticals Zynerba Pharmaceuticals
ZYNE
- - $ 55.5 M usaUSA
Eagle Pharmaceuticals Eagle Pharmaceuticals
EGRX
- -39.89 % $ 27.7 M usaUSA
PetIQ PetIQ
PETQ
- 1.64 % $ 400 M usaUSA
Tricida Tricida
TCDA
- - $ 3.25 M usaUSA
DURECT Corporation DURECT Corporation
DRRX
- - $ 50.1 M usaUSA
Athenex Athenex
ATNX
- -23.39 % $ 1.76 M usaUSA
PLx Pharma PLx Pharma
PLXP
- -27.8 % $ 2.56 M usaUSA
Catalent Catalent
CTLT
- - $ 11.5 B usaUSA
Endo International plc Endo International plc
ENDP
- - $ 28.9 M irlandaIrlanda
OptiNose OptiNose
OPTN
- - $ 1.08 B usaUSA
Radius Health Radius Health
RDUS
- - $ 1.42 B usaUSA
Recro Pharma Recro Pharma
REPH
- -4.76 % $ 65.3 M usaUSA
Canopy Growth Corporation Canopy Growth Corporation
CGC
$ 0.65 -3.6 % $ 194 M canadaCanada
Aurora Cannabis Aurora Cannabis
ACB
$ 5.24 0.87 % $ 287 M canadaCanada
Harrow Health Harrow Health
HROW
$ 26.86 3.15 % $ 987 M usaUSA
Cumberland Pharmaceuticals Cumberland Pharmaceuticals
CPIX
$ 5.26 4.99 % $ 78.1 M usaUSA
Relmada Therapeutics Relmada Therapeutics
RLMD
$ 3.92 3.98 % $ 155 M usaUSA
Emergent BioSolutions Emergent BioSolutions
EBS
$ 6.04 3.25 % $ 323 M usaUSA
Evolus Evolus
EOLS
$ 6.86 0.88 % $ 442 M usaUSA
Bausch Health Companies Bausch Health Companies
BHC
$ 8.19 2.7 % $ 3.04 B canadaCanada
OrganiGram Holdings OrganiGram Holdings
OGI
$ 0.88 -5.39 % $ 83.9 M canadaCanada
SCYNEXIS SCYNEXIS
SCYX
$ 3.51 6.21 % $ 175 M usaUSA
HEXO Corp. HEXO Corp.
HEXO
- 2.45 % $ 38.1 M canadaCanada
Calliditas Therapeutics AB (publ) Calliditas Therapeutics AB (publ)
CALT
- -0.1 % $ 2.03 B schwedenSchweden
Sonoma Pharmaceuticals Sonoma Pharmaceuticals
SNOA
$ 1.12 5.1 % $ 1.89 M usaUSA
TherapeuticsMD TherapeuticsMD
TXMD
$ 1.7 -0.58 % $ 19.7 M usaUSA
AcelRx Pharmaceuticals AcelRx Pharmaceuticals
ACRX
- 7.5 % $ 6.35 M usaUSA